# 2) Biological Warfare Defense Therapeutics - Enhanced Biological Defense

**R-2A activity** of project MT3 — Mitigate (ATD)  
**Program element:** 0603384BP — Chemical and Biological Defense Program - Advanced Development  
**Component:** Defense-Wide · **Budget Activity:** 3  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0603384BP/MT3/a1  
**Parent:** https://hitchintel.com/programs/0603384BP/MT3

## Summary

This activity requests $20.0M in FY2027, 34% of project MT3, up 0.0% on FY2026. The R-2A exhibit describes it across FY2025–FY2027, including what the FY2027 money is planned to buy.

## What the FY2027 request buys

**FY2027 planned work.** - Finalize development of comprehensive searchable repository for repurposed drug candidates containing supporting data for biothreat pathogen applications. - Advance broad spectrum, repurposed pharmaceutical candidates with biodefense evidence toward later-stage development or clinical practice guideline establishment. - Initiate development of broad spectrum nanoparticle delivery platform for therapeutic encapsulation and formulation. - Initiate development of human-relevant multi-organ system incorporating both innate and adaptive immune components.

## Before the request year

**FY2026 plans — current year.** -Continue the development of 5-10 repurpose broad spectrum capabilities. -Continue to create and sustain curated, searchable databases of molecules with toxicity, drug development and efficacy data to decrease timeline in MCM fielding. -Continue to develop host-directed pathogen agnostic therapies directed at mitigation of presentation of disease. -Continue to develop testing platform to examine off-target effects and/or unintended consequences of therapies directed against host targets.

**FY2025 accomplishments.** - Continued studies demonstrating the broad-spectrum efficacy of an FDA-approved muscle weakness treatment for reversing toxin-induced muscular paralysis. - Finalized studies supporting the application of an FDA-approved clotting disorder treatment as a therapeutic intervention for vascular leakage in hemorrhagic fevers. - Initiated studies generating biodefense data for a viral entry inhibitor currently in Phase 2 clinical development. - Concluded efficacy assessments of approved antimicrobials against biothreat pathogens to guide clinical practice recommendations.

## Funding

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 20.9 |
| FY2026 | Enacted | 20.0 |
| FY2027 | Request | 20.0 |

> Prior, current and budget year only — an R-2A activity carries no five-year plan. It sums exactly into its project in the request year and not necessarily in any other.

## Other activities in project MT3

- [1) Biological Warfare Defense Therapeutics](https://hitchintel.com/programs/0603384BP/MT3/a0) — FY2027 18.2
- 8) Equipment Decontamination — FY2027 8.6
- 12) Equipment Decontamination - Enhanced Biological Defense — FY2027 5.0
- 6) Reactivators of Acetylcholinesterase as Therapeutics — FY2027 3.0
- 3) Discovery of Medical countermeasures Against New and Emerging threats - Enhanced Biological Defense — FY2027 2.5
- 13) Critical Area Decontamination - Enhanced Biological Defense — FY2027 1.0
- 7) Critical Area Decontamination — FY2027 0.8
- 9) Multifunctional Materials for Protection — FY2027 0.1
- 4) Chemically Reactive Ocular, Wound and Dermal Therapeutics — FY2027 —
- 5) Emerging and Pharmaceutical-based Agent Threats — FY2027 —
- 10) Enhanced Survivability Coatings — FY2027 —
- 11) Personnel Decontamination — FY2027 —

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibit R-2A, PE 0603384BP project MT3 (PB PB2027). Narrative is the government's own text.
- **No marks, no contractors at this grain** — congressional marks land on the program element and R-3 performers on the project.
- **MCP:** `mcp.hitchintel.com` — `budget_get_activity`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*